Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Secon…